Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to compare oral rivaroxaban with injectable enoxaparin in orthopaedic trauma patients to determine if orally administered rivaroxaban once daily carries greater compliance and overall satisfaction than enoxaparin self-administered by subcutaneous injection once daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Florida Orthopaedic Institute
• Collaborator: Orthopaedic Trauma Association
• Treatments: Enoxaparin; Rivaroxaban

Criteria

Inclusion Criteria:

• • Orthopaedic trauma patients deemed by the attending, treating surgeon to require an extended duration of venous thromboembolism chemoprophylaxis beyond that provided as an inpatient.

• Patients being discharged directly to home.

Exclusion Criteria:

• • Patients being discharged to a rehabilitation center or a skilled nursing facility.

• A contraindication to anticoagulation such as traumatic or other hemorrhage, as determined by the treating surgeon and/or consulting services.

• Ongoing venous thromboembolism treatment or extended prophylaxis (i.e. past history of multiple deep vein thrombosis/pulmonary embolism) for current or recent deep vein thrombosis, pulmonary embolism or other coagulopathic disorder

• Chronic anticoagulation for atrial fibrillation or other medical disorder requiring chronic anticoagulation therapy.

• Perceived low-risk patients requiring only aspirin or no pharmacological venous thromboembolism prophylaxis.

• Pregnant, prisoner, under 18 years old, or do not speak English